REG - CVS Group plc - Transaction in Own Shares
11/11/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251111:nRSK9502Ga&default-theme=true
RNS Number : 9502G CVS Group plc 11 November 2025
11 November 2025
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares
CVS announces that on 10 November 2025 it purchased the following number of
its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg,
Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the
terms of the share buyback programme announced on 24 October 2025 (the "Share
Buyback Programme").
Date of purchase: 10/11/2025
Aggregate number of Ordinary Shares purchased: 23,628
Lowest price paid per share (GBp): 1,206.00
Highest price paid per share (GBp): 1,218.00
Volume weighted average price paid per share (GBp): 1,209.54
CVS intends to cancel all of the purchased Ordinary Shares.
Total voting rights:
Due to an administrative error, the issued share capital was incorrectly
stated on 10/11/2025 in RNS number 8395G. Following adjusting for the
administrative error, settlement of the above purchases and cancellation of
the Ordinary Shares purchased and including any allotments that may have been
made during the day relating to the exercising of employee shares options, the
Company will have 71,409,567 Ordinary Shares in issue, each with one voting
right. The Company holds no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 71,409,567 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, CVS under the Financial Conduct Authority's
Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has
repurchased 331,216 Ordinary Shares in aggregate at a weighted average price
of 1,266.46 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation), as it forms part of Retained EU Law as defined in the
European Union (Withdrawal) Act 2018, the table below contains detailed
information of the individual trades made by Berenberg as part of the Share
Buyback Programme.
Individual transactions:
Number of Transaction price (GBp share) Time of Transaction Trading Venue
Ordinary Shares purchased transaction (UK Time) reference number
254 1214 10/11/2025 08:00:41 1330435455977728 XLON
231 1214 10/11/2025 08:04:22 1330435455978670 XLON
73 1214 10/11/2025 08:04:22 1330435455978671 XLON
72 1214 10/11/2025 08:20:52 1330435455980797 XLON
84 1218 10/11/2025 09:08:14 1330435455984910 XLON
81 1216 10/11/2025 09:09:16 1330435455985005 XLON
314 1214 10/11/2025 09:13:12 1330435455985397 XLON
239 1214 10/11/2025 09:13:12 1330435455985400 XLON
160 1212 10/11/2025 09:13:24 1330435455985411 XLON
88 1210 10/11/2025 09:13:54 1330435455985450 XLON
72 1212 10/11/2025 09:16:40 1330435455985630 XLON
124 1212 10/11/2025 09:17:00 1330435455985640 XLON
72 1216 10/11/2025 10:51:05 1330435455992013 XLON
72 1214 10/11/2025 10:56:45 1330435455992420 XLON
72 1216 10/11/2025 11:22:06 1330435455993762 XLON
72 1214 10/11/2025 11:45:25 1330435455995101 XLON
972 1212 10/11/2025 11:48:53 1330435455995373 XLON
220 1212 10/11/2025 11:55:03 1330435455995652 XLON
776 1212 10/11/2025 11:55:03 1330435455995653 XLON
731 1210 10/11/2025 12:38:10 1330435455998132 XLON
283 1210 10/11/2025 12:38:10 1330435455998133 XLON
463 1210 10/11/2025 12:49:16 1330435455998850 XLON
585 1210 10/11/2025 12:49:16 1330435455998851 XLON
1073 1208 10/11/2025 13:25:17 1330435456001570 XLON
1095 1210 10/11/2025 13:50:44 1330435456003374 XLON
6 1210 10/11/2025 13:50:44 1330435456003376 XLON
530 1210 10/11/2025 13:50:44 1330435456003377 XLON
417 1210 10/11/2025 13:50:44 1330435456003378 XLON
77 1208 10/11/2025 13:52:26 1330435456003427 XLON
221 1208 10/11/2025 14:06:05 1330435456004522 XLON
190 1208 10/11/2025 14:06:06 1330435456004526 XLON
408 1208 10/11/2025 14:34:26 1330435456008276 XLON
208 1208 10/11/2025 14:34:26 1330435456008279 XLON
114 1206 10/11/2025 14:34:38 1330435456008320 XLON
66 1206 10/11/2025 14:34:38 1330435456008321 XLON
72 1208 10/11/2025 14:51:22 1330435456011792 XLON
180 1206 10/11/2025 14:56:00 1330435456012663 XLON
334 1206 10/11/2025 14:56:00 1330435456012668 XLON
180 1206 10/11/2025 14:56:00 1330435456012671 XLON
596 1206 10/11/2025 14:56:00 1330435456012673 XLON
180 1206 10/11/2025 14:56:00 1330435456012675 XLON
577 1206 10/11/2025 14:56:00 1330435456012677 XLON
180 1206 10/11/2025 14:56:00 1330435456012679 XLON
704 1206 10/11/2025 14:56:00 1330435456012681 XLON
10 1210 10/11/2025 15:13:20 1330435456015137 XLON
170 1210 10/11/2025 15:13:20 1330435456015138 XLON
10 1210 10/11/2025 15:13:20 1330435456015139 XLON
180 1210 10/11/2025 15:13:20 1330435456015140 XLON
180 1210 10/11/2025 15:13:20 1330435456015141 XLON
180 1210 10/11/2025 15:13:20 1330435456015142 XLON
180 1210 10/11/2025 15:13:20 1330435456015143 XLON
180 1210 10/11/2025 15:13:20 1330435456015144 XLON
180 1210 10/11/2025 15:13:20 1330435456015145 XLON
180 1210 10/11/2025 15:13:20 1330435456015146 XLON
180 1210 10/11/2025 15:13:20 1330435456015147 XLON
168 1210 10/11/2025 15:13:20 1330435456015148 XLON
12 1210 10/11/2025 15:13:20 1330435456015149 XLON
168 1210 10/11/2025 15:13:20 1330435456015150 XLON
180 1210 10/11/2025 15:13:20 1330435456015151 XLON
225 1210 10/11/2025 15:13:20 1330435456015152 XLON
180 1210 10/11/2025 15:13:20 1330435456015153 XLON
99 1210 10/11/2025 15:13:20 1330435456015154 XLON
81 1210 10/11/2025 15:13:20 1330435456015155 XLON
180 1210 10/11/2025 15:13:20 1330435456015156 XLON
12 1210 10/11/2025 15:13:20 1330435456015157 XLON
168 1210 10/11/2025 15:17:51 1330435456015845 XLON
1227 1210 10/11/2025 15:17:51 1330435456015846 XLON
465 1210 10/11/2025 15:17:51 1330435456015848 XLON
180 1210 10/11/2025 15:17:51 1330435456015849 XLON
1475 1210 10/11/2025 15:17:51 1330435456015850 XLON
441 1210 10/11/2025 15:17:51 1330435456015851 XLON
198 1210 10/11/2025 15:40:42 1330435456019138 XLON
464 1210 10/11/2025 15:40:42 1330435456019139 XLON
170 1208 10/11/2025 15:52:16 1330435456021147 XLON
168 1208 10/11/2025 15:52:16 1330435456021148 XLON
175 1206 10/11/2025 15:52:31 1330435456021193 XLON
313 1206 10/11/2025 15:52:31 1330435456021194 XLON
72 1210 10/11/2025 16:01:51 1330435456023043 XLON
1098 1208 10/11/2025 16:04:26 1330435456023451 XLON
200 1208 10/11/2025 16:04:26 1330435456023452 XLON
180 1208 10/11/2025 16:24:27 1330435456027673 XLON
86 1208 10/11/2025 16:24:27 1330435456027674 XLON
94 1208 10/11/2025 16:24:27 1330435456027675 XLON
1 1208 10/11/2025 16:24:27 1330435456027676 XLON
Contacts
CVS Group
plc
via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Peel Hunt LLP (Nominated Adviser & Joint
Broker)
+44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Berenberg (Joint Broker)
+44 (0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Camarco (Financial
PR)
cvsg@camarco.co.uk
Ginny Pulbrook
+44
(0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia. CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSGPGUAGUPAGMU
Copyright 2019 Regulatory News Service, all rights reservedRecent news on CVS
See all newsREG - CVS Group plc - Transaction in Own Shares
AnnouncementREG - CVS Group plc - Standard form for notification of major holdings
AnnouncementREG - CVS Group plc - Transaction in Own Shares
AnnouncementREG - CVS Group plc - Transaction in Own Shares
AnnouncementREG - CVS Group plc - PDMR Dealing
Announcement